ELTD1 Antibody

What is ELTD1 and why is it significant in scientific research?

ELTD1 (epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1) is a member of the G-protein coupled receptors (GPCRs) superfamily that was discovered in 2001. It has gained significance in research due to its role in both physiological and pathological angiogenesis. ELTD1 is highly expressed in cardiomyocytes, blood vessels, and bronchi's smooth muscle cells . It is also distributed in various tissues including adipose tissue, brain, liver, skeletal muscle, gastrointestinal tract, and pancreas . Research has revealed its involvement in several processes including angiogenesis, cardiac hypertrophy, sensitivity of anesthetics, and various disease conditions, making it a promising biomarker and therapeutic target .

How does ELTD1 expression vary across normal tissues versus pathological conditions?

ELTD1 expression exhibits distinctive patterns in normal versus pathological tissues:

Normal tissues: ELTD1 is highly expressed in endothelial cells, vascular smooth muscle cells, and cardiomyocytes under physiological conditions . It shows notable distribution in adipose tissue, brain, liver, skeletal muscle, gastrointestinal tract, and pancreas .

Pathological conditions: Significant upregulation of ELTD1 is observed in:

• Multiple cancer types, including glioblastoma, renal, colorectal, head and neck, and ovarian cancers

• CNS inflammation models such as experimental autoimmune encephalomyelitis (EAE)

• Cardiac hypertrophy models following pressure overload

What are the validated applications for ELTD1 antibodies in laboratory settings?

ELTD1 antibodies have been validated for several laboratory applications with specific methodological considerations:

Western Blot: Validated at dilutions of 1:500-1:1000, allowing detection of ELTD1 protein expression levels in various tissues and cell lines . This technique has been used to confirm knockdown or overexpression of ELTD1 in functional studies .

Immunohistochemistry (IHC): Used at 1:500-1:1000 dilutions for both fresh frozen and paraffin-embedded samples . IHC has been crucial in localizing ELTD1 expression in tumor tissues versus normal tissues and correlating expression with clinicopathological parameters .

Molecular-targeted MRI: ELTD1 antibodies (both polyclonal and monoclonal) have been conjugated to biotin-BSA-Gd-DTPA constructs for in vivo imaging of ELTD1 expression in animal models . This technique enables non-invasive assessment of ELTD1 levels in disease models.

Therapeutic applications: Both polyclonal and monoclonal antibodies against ELTD1 have been used in experimental models, particularly for glioblastoma, with monoclonal antibodies demonstrating superior specificity and efficacy .

How do monoclonal and polyclonal anti-ELTD1 antibodies compare in therapeutic efficacy for glioblastoma models?

Comparative studies between monoclonal and polyclonal anti-ELTD1 antibodies have revealed significant differences in their therapeutic efficacy for glioblastoma:

Tumor volume reduction: Monoclonal anti-ELTD1 therapy resulted in significantly greater reduction in tumor volumes (P = .0067) compared to polyclonal therapy (P = .0384) .

Vascular normalization: Both antibodies improved relative cerebral blood flow (rCBF), but monoclonal antibody treatment showed more effective normalization of tumor vasculature .

Binding specificity: Molecular-targeted MRI revealed that monoclonal anti-ELTD1 antibodies had significantly higher binding specificity for tumor regions compared to polyclonal antibodies. The T1 relaxation (P = .0002) and signal intensity (P = .008) were significantly increased with monoclonal antibody probes, while polyclonal probes only significantly increased T1 relaxation (P = .0307) without significantly affecting signal intensity (P = .0602) .

Long-term effects: Monoclonal antibody probes demonstrated more profound and sustained effects compared to polyclonal antibodies .

These findings highlight the importance of antibody optimization in developing effective ELTD1-targeted therapies.

What are the methodological challenges in developing and validating anti-ELTD1 monoclonal antibodies for therapeutic applications?

Developing effective anti-ELTD1 monoclonal antibodies for therapeutic applications faces several methodological challenges:

Target domain selection: ELTD1 contains multiple domains (EGF-like, GPCR-autoproteolysis inducing domain, and seven-transmembrane domain), requiring careful selection of the target epitope for antibody generation. In successful approaches, researchers have used the recombinant extracellular domain of human ELTD1 (Glu20-Leu406) for immunization .

Cross-species reactivity: Developing antibodies that recognize both human and mouse ELTD1 is essential for translational research. This requires careful sequence analysis and selection of conserved epitopes between species .

Antibody format optimization: Various formats (scFv, scFv-Fc fusion, full IgG) must be evaluated for optimal tissue penetration and efficacy, particularly for brain tumors where the blood-brain barrier is a concern .

Production and purification challenges: The search results describe a specific production method using HEK293F cells for expression followed by protein A/KappaSelect affinity chromatography purification . This system must be optimized for yield and quality.

Validation across multiple platforms: Comprehensive validation requires assessment of binding specificity via enzyme immunoassay, Western blot, immunohistochemistry, and in vivo molecular imaging .

In vivo delivery optimization: Finding the optimal dosage (2 mg/kg was effective in mouse models), administration route, and treatment schedule (every 3-4 days) requires extensive testing .

Mechanism of action determination: Understanding how anti-ELTD1 antibodies exert their effects (e.g., through Notch1 signaling disruption) requires complex signaling studies and RNA-seq analysis .

How does ELTD1 mechanistically contribute to different pathological processes across cancer types and other diseases?

ELTD1 exhibits diverse mechanistic roles across different pathological contexts:

In Glioblastoma:

• Promotes tumor angiogenesis through interaction with VEGFR2

• Interacts with and disrupts Notch1 signaling pathway

• Influences JAK/STAT3/HIF-1α signaling to control proliferation, migration, and invasion of glioma cells

• Targeted by miR-139-5p which inhibits tumor progression

In Colorectal Cancer:

• Promotes cell migration and invasion capabilities

• Activates MMP2 to enhance metastatic potential

• Associated with lymph node metastasis and poor prognosis

In Cardiac Hypertrophy:

• ELTD1 deficiency exacerbates cardiac hypertrophy in response to pressure overload

• Mechanistically linked to enhanced ERK and JNK phosphorylation pathways

• Influences fibrosis mediators (including transforming growth factor-β1, TGFβ2, and connective tissue growth factor)

In Multiple Sclerosis:

• Serves as a biomarker for CNS inflammation

• Associated with blood-brain barrier disruption and altered cerebral blood flow

• Particularly detected in the corpus callosum of experimental autoimmune encephalomyelitis models

This mechanistic diversity highlights the context-dependent roles of ELTD1 and the importance of tissue-specific research approaches.

What are the effects of ELTD1 knockout or silencing on cellular signaling pathways in different experimental models?

ELTD1 knockout or silencing produces distinct effects on signaling pathways across different experimental models:

In cardiac models:

• ELTD1 knockout (KO) mice exhibited enhanced phosphorylation of MEK1/2-ERK1/2 and JNK1/2 after aortic banding, while p38-MAPK phosphorylation remained unaffected

• Activation of Akt was amplified by aortic banding but showed no difference between wildtype and KO groups

• ELTD1 deficiency resulted in increased expression of fibrosis mediators including TGFβ1, TGFβ2, and connective tissue growth factor

In cancer models:

• In hepatocellular carcinoma, ELTD1 silencing drastically reduced cell invasiveness

• In retinoblastoma, disrupting ELTD1 reduced in vitro cell migration and in vivo metastasis

• In glioblastoma, ELTD1 silencing induced cell death

• In colorectal cancer cells (HT29, RKO, and HCT116), ELTD1 knockdown decreased migration and invasion capabilities

Gene expression changes after anti-ELTD1 therapy:
The following table shows key genes affected by anti-ELTD1 mAb therapy:

This comprehensive analysis of pathway alterations is crucial for understanding ELTD1's role and developing targeted interventions .

How does anti-ELTD1 antibody therapy compare with established anti-angiogenic treatments like bevacizumab (anti-VEGF) in preclinical models?

Anti-ELTD1 antibody therapy demonstrates several distinct advantages over established anti-VEGF treatments in preclinical models:

Vascular normalization: While both therapies target angiogenesis, anti-ELTD1 antibodies restore vascularity to normal patterns, as measured by relative cerebral blood flow. In contrast, anti-VEGF treatment often leads to more drastic vascular reduction .

Hemorrhagic complications: A critical advantage of anti-ELTD1 therapy is the absence of hemorrhaging, which is a significant side effect observed with anti-VEGF treatments like bevacizumab. Histological iron staining confirmed that anti-ELTD1 mAb therapy has no associated hemorrhaging, whereas bevacizumab causes notable hemorrhaging in tumor models .

Effect on Notch signaling: Anti-ELTD1 therapy, particularly with monoclonal antibodies, significantly decreases Notch levels and restores them to normal (contralateral) levels. In contrast, bevacizumab (anti-VEGF) has no effect on Notch levels .

Tumor microenvironment: Unlike anti-VEGF treatments that primarily target vascular endothelial cells, anti-ELTD1 therapy appears to alter the tumor microenvironment more broadly, potentially offering more comprehensive tumor control .

Efficacy in aggressive models: Anti-ELTD1 mAb therapy has demonstrated efficacy in highly aggressive orthotopic rodent xenograft models of glioblastoma (G55), reducing tumor volumes and increasing animal survival even in models with fast doubling times .

These comparisons highlight the potential of anti-ELTD1 therapy as an alternative or complementary approach to existing anti-angiogenic treatments.

What is the rationale for using ELTD1 as a biomarker in multiple sclerosis, and what methodologies are most effective for its detection?

The rationale for ELTD1 as a biomarker in multiple sclerosis (MS) is based on several key observations:

Shared vascular pathology: Both MS and glioblastoma, despite being distinct diseases, share perturbations in CNS vasculature as hallmarks. RNA-seq analysis of preclinical glioblastoma models identified that molecular pathways affected by anti-ELTD1 antibody therapy are also associated with MS .

Consistent detection in MS models: ELTD1 is readily detected in the brains of mice with experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. It is predominantly found in the corpus callosum, making it a regionally specific biomarker .

Association with BBB disruption: In EAE mice, ELTD1 expression correlates with compromised blood-brain barrier (BBB) integrity as demonstrated by contrast-enhanced MRI. This is particularly relevant as BBB disruption is a key feature of MS pathology .

Correlation with altered blood flow: EAE mice show altered relative cerebral blood flow (rCBF) in both brain and cervical spinal cord regions, which correlates with ELTD1 expression patterns .

Effective detection methodologies:

• Molecular-targeted MRI: Using antibodies against ELTD1 conjugated to contrast agents (biotin-BSA-Gd-DTPA) allows non-invasive in vivo assessment of ELTD1 expression patterns in the CNS .

• Immunohistochemistry: Direct detection of ELTD1 expression in brain and spinal cord tissues, with particular attention to the corpus callosum region .

• Perfusion imaging: Measurement of relative cerebral blood flow using MRI techniques to indirectly assess the consequence of ELTD1 expression on vascular function .

These findings suggest that ELTD1 may serve as a promising biomarker for CNS inflammation in MS, with potential applications in diagnosis, disease monitoring, and therapeutic development.

What are the most significant pathways altered by anti-ELTD1 antibody treatment in cancer models, and how might these inform combination therapy approaches?

Anti-ELTD1 antibody treatment affects several significant pathways in cancer models, offering insights for potential combination therapies:

Notch signaling pathway:

• Anti-ELTD1 mAb therapy significantly decreases Notch levels in tumor tissue

• ELTD1 appears to interact with and interrupt Notch1 signaling

• This suggests potential synergy with established Notch inhibitors like gamma-secretase inhibitors

JAK/STAT3/HIF-1α signaling pathway:

• ELTD1 overexpression activates this pathway in glioma, promoting proliferation, migration, and invasion

• Anti-ELTD1 therapy may disrupt this pathway, suggesting combination with specific JAK/STAT inhibitors could enhance efficacy

Pro-angiogenic pathways:

• RNA-seq analysis of anti-ELTD1 treated tumors showed downregulation of pro-angiogenic factors:

  • BMP2 (bone morphogenetic protein 2) - normally increases vascular density

  • APLN (apelin) - promotes angiogenesis and may contribute to temozolomide resistance

• Suggests potential combination with other anti-angiogenic approaches targeting different mechanisms

Cell adhesion and invasion pathways:

• L1CAM downregulation after anti-ELTD1 therapy is notable as L1CAM is required for growth of CD133+ glioma cells

• Downregulation of PRICKLE1, which plays a role in tumor cell motility as a negative regulator of Wnt signaling

• Points to possible combinations with therapies targeting cell adhesion molecules or Wnt pathway inhibitors

Gene expression changes in key cancer-related genes:
The table below summarizes the most significant gene expression changes following anti-ELTD1 mAb therapy:

These pathway alterations provide a rational basis for combination therapies that could target complementary mechanisms to enhance anti-cancer efficacy .

What experimental evidence supports the utility of ELTD1 as a predictive biomarker for treatment response in different cancer types?

Experimental evidence supporting ELTD1 as a predictive biomarker for treatment response comes from several cancer types:

Renal Cell Carcinoma (RCC):

• A recent study (2021) by Marjut Niinivirta et al. reported that high expression of ELTD1 in tumor vasculature predicts a favorable response to sunitinib treatment in patients with metastatic renal cell cancer

• Significantly higher progression-free survival (PFS) was observed after sunitinib treatment in patients with high ELTD1 expression compared to those with low ELTD1 expression

• This indicates ELTD1 may serve as a predictive rather than merely prognostic marker in RCC

Glioblastoma (GBM):

• In G55 xenograft glioma models, baseline ELTD1 expression levels correlated with response to anti-ELTD1 antibody therapy

• Tumors with higher ELTD1 expression showed more pronounced responses to anti-ELTD1 therapy in terms of tumor volume reduction and survival benefit

• Molecular-targeted MRI using anti-ELTD1 probes could potentially predict therapy response by quantifying ELTD1 levels before treatment initiation

Colorectal Cancer (CRC):

• Analysis by Abdul Aziz et al. identified ELTD1 as part of a 19-gene expression signature that predicted poor prognosis in CRC, which was more accurate than traditional Dukes staging

• This suggests potential utility in identifying patients who might benefit from more aggressive treatment approaches

Head and Neck Cancer:

• While findings in head and neck cancers have been somewhat contradictory regarding prognosis, ELTD1 expression correlates with high microvascular density, suggesting it could predict response to anti-angiogenic therapies

The experimental evidence across multiple cancer types suggests that ELTD1 expression patterns may serve as useful predictive biomarkers for treatment selection and response monitoring, particularly for therapies targeting angiogenesis.

What are the major unresolved questions regarding ELTD1's structure-function relationship and its activating ligands?

Despite progress in ELTD1 research, several critical knowledge gaps remain regarding its structure-function relationship and ligand interactions:

Unknown activating ligands:

• The endogenous ligand(s) that activate ELTD1 remain unidentified, presenting a significant gap in understanding its signaling mechanisms

• As noted in the literature, "relatively little is known about the receptor intracellular signaling or its activating ligand"

Structural characterization deficits:

• The authors emphasize that "available studies about X-ray crystal structures of ELTD1/ligand complex or ELTD1/intracellular proteins complexes, to validate the binding site on the protein-protein interface, does not practically exist in the literature"

• Lack of structural data hampers rational drug design efforts targeting ELTD1

Domain-specific functions:

• While ELTD1 contains EGF-like domains, a GPCR-autoproteolysis inducing domain, and seven-transmembrane regions, the specific contributions of each domain to its function remain poorly understood

• The antibody used in successful studies was developed against a recombinant protein corresponding to a specific amino acid sequence, but the functional significance of this region is not fully characterized

Signaling pathway integration:

• How ELTD1 interacts with other angiogenesis-related proteins and pathways (like VEGFR and DLL4) requires further investigation

• The authors specifically ask: "Are ELTD1 and other angiogenesis genes reciprocally affected? What other ligands may bind to ELTD1 receptor, apart from VEGFR and DLL4? What other molecules are involved in the signaling pathways of ELTD1?"

Tissue-specific signaling differences:

• How ELTD1 signaling differs between normal tissues and various pathological conditions remains unclear

• Whether ELTD1 employs different downstream effectors in different cellular contexts (endothelial cells versus tumor cells) requires further exploration

Resolving these questions would significantly advance both fundamental understanding of ELTD1 biology and therapeutic development efforts.

What are the most promising methodological approaches for investigating ELTD1's role in disease progression and treatment response?

Several methodological approaches show particular promise for advancing ELTD1 research:

Advanced imaging technologies:

• Molecular-targeted MRI (mt-MRI) using anti-ELTD1 antibodies conjugated to contrast agents (biotin-BSA-Gd-DTPA) has proven effective for non-invasive visualization of ELTD1 expression in vivo

• Perfusion MRI measuring relative cerebral blood flow (rCBF) offers insights into the functional consequences of ELTD1 expression/inhibition on vasculature

• These techniques allow longitudinal monitoring in the same subject, reducing experimental variability

RNA sequencing and pathway analysis:

• RNA-seq has successfully identified downstream effects of anti-ELTD1 therapy, revealing alterations in genes related to angiogenesis, cell adhesion, and signaling pathways

• This approach enables hypothesis generation regarding mechanisms of action and potential combination therapies

Genetic manipulation models:

• ELTD1 knockout mice have provided valuable insights into its role in cardiac hypertrophy

• CRISPR/Cas9 gene editing could enable more precise investigations of domain-specific functions through targeted mutations

Single-cell analysis techniques:

• Given ELTD1's complex expression patterns across cell types, single-cell RNA-seq and proteomics could reveal cell-specific roles and signaling partners

• This approach could help resolve contradictory findings regarding ELTD1's prognostic significance in different cancer types

Patient-derived xenograft models:

• Beyond established cell lines like G55, patient-derived xenografts would better capture the heterogeneity of ELTD1 expression and its impact on treatment response

• This approach is particularly relevant given the correlation between ELTD1 expression and treatment outcomes in some cancers

Antibody engineering approaches:

• Building on the success of optimized monoclonal antibodies, further engineering (scFv fragments, bispecific antibodies) could enhance tissue penetration and efficacy

• These approaches could be particularly valuable for targeting ELTD1 in CNS disorders where blood-brain barrier penetration is challenging

These methodological approaches, used in combination, offer the best prospects for advancing ELTD1 research toward clinical applications.

How might current findings on ELTD1 inform the development of novel therapeutic approaches beyond antibody-based treatments?

Current ELTD1 research suggests several promising therapeutic approaches beyond antibody-based treatments:

Small molecule inhibitors:

• Despite the note that "small-molecule inhibitors for ELTD1 have not yet been identified" , structural studies could enable rational design of such compounds

• Target-based drug discovery focusing on specific domains (EGF-like, GPCR-autoproteolysis inducing, seven-transmembrane) could yield selective inhibitors with improved tissue penetration compared to antibodies

RNA-based therapeutics:

• Evidence that "miR-139-5p inhibited tumor progression by targeting ELTD1" suggests microRNA-based approaches could be effective

• siRNA or antisense oligonucleotides specifically targeting ELTD1 could achieve gene silencing effects similar to knockdown studies that showed reduced invasion and migration in cancer models

Peptide antagonists:

• Design of peptide antagonists based on the interaction between ELTD1 and its binding partners (like Notch1) could selectively disrupt pathological signaling while preserving physiological functions

• The finding that ELTD1 "has the ability to interact with and interrupt Notch1 signalling" provides a starting point for such designs

Combination therapy strategies:

• RNA-seq data identifying genes affected by anti-ELTD1 therapy (like BMP2, APLN, L1CAM) suggest rational combination approaches targeting complementary pathways

• Given ELTD1's role in angiogenesis, combining ELTD1-targeted therapies with immune checkpoint inhibitors could enhance efficacy by normalizing tumor vasculature and improving immune cell infiltration

Cell-based therapy approaches:

• Engineering T cells or NK cells to recognize ELTD1-expressing cells could target tumor vessels or cancer cells overexpressing this marker

• This approach could be particularly valuable for cancers where ELTD1 overexpression correlates with metastasis and poor outcomes

Theranostic approaches:

• Building on successful molecular imaging with anti-ELTD1 antibodies , theranostic agents combining imaging capabilities with therapeutic payloads could enable personalized treatment

• Such approaches could be particularly valuable for heterogeneous diseases like glioblastoma where treatment response varies significantly between patients

These diverse therapeutic strategies could overcome limitations of antibody-based approaches, especially for CNS indications where antibody penetration is limited.

What are the critical methodological considerations when designing experiments to investigate ELTD1's role in different disease models?

Designing robust experiments to investigate ELTD1 in disease models requires addressing several critical methodological considerations:

Model selection and relevance:

• Different disease models express ELTD1 at varying levels - for example, G55 xenograft glioma models show high ELTD1 expression while other models may not

• Cell line passage number significantly affects ELTD1-related phenotypes - as noted in one study, "this current study used low-passaged G55 cells that appeared more aggressive due to their faster doubling period"

• Consideration of orthotopic versus heterotopic models is crucial, particularly for CNS diseases where the blood-brain barrier impacts drug delivery

Antibody validation and specificity:

• When using anti-ELTD1 antibodies, rigorous validation through multiple techniques is essential

• Specificity should be verified through approaches like "Protein Array containing target protein plus 383 other non-specific proteins"

• For therapeutic studies, comparison between polyclonal and monoclonal antibodies is important given their different efficacy profiles

Appropriate controls and baselines:

• Include proper controls for antibody specificity (e.g., non-specific IgG controls in imaging studies)

• Establish clear baselines for ELTD1 expression in normal tissues corresponding to the disease model

• For cardiac studies, appropriate sham operations are necessary to control for surgical effects apart from the disease model

Timing considerations:

• Temporal dynamics of ELTD1 expression should be monitored, as expression patterns may change during disease progression

• In therapeutic studies, intervention timing is critical - studies begin treatment "once tumours reached 6-7 mm³"

• Appropriate follow-up periods must be established based on the disease model's progression rate

Methodological triangulation:

• Combining multiple techniques provides stronger evidence - successful studies use combinations of:

  • In vivo imaging (mt-MRI, perfusion MRI)

  • Molecular analyses (RNA-seq, qRT-PCR, Western blot)

  • Histological assessments (IHC, microvessel density quantification)

  • Functional assessments (survival, tumor volumes, invasiveness)

Reproducibility and statistical considerations:

• Sample sizes must be sufficient for detecting differences in ELTD1-related outcomes

• Statistical analyses should be appropriate for the experimental design and data distribution

• Experimental endpoints should be clearly defined and consistently applied across experimental groups

Addressing these methodological considerations is essential for generating reliable and translatable data on ELTD1's role in disease.

How has our understanding of ELTD1 evolved over the past decade, and what are the key remaining knowledge gaps?

Our understanding of ELTD1 has evolved substantially since its discovery in 2001, with accelerated progress in the past decade revealing its multifaceted roles in both normal physiology and pathological conditions.

Key evolution points:

• From obscurity to recognized significance: Initially, ELTD1 was a poorly studied member of the GPCR family. Recent research has established its importance in angiogenesis and various disease processes .

• Expansion of known expression patterns: Initially identified in cardiomyocytes, research has mapped ELTD1 expression across multiple tissues and revealed its upregulation in various pathological states .

• Therapeutic potential recognition: The development and testing of both polyclonal and optimized monoclonal antibodies against ELTD1 has demonstrated therapeutic potential, particularly in glioblastoma models .

• Cross-disease relevance: Originally studied in isolation, ELTD1 is now recognized as having roles in multiple conditions including various cancers, cardiac hypertrophy, and multiple sclerosis .

• Mechanistic insights: Progress from correlative studies to mechanistic investigations has revealed interactions with important signaling pathways including Notch, JAK/STAT3/HIF-1α, and MAPK pathways .

Remaining knowledge gaps:

• Ligand identification: The endogenous ligand(s) that activate ELTD1 remain unidentified, presenting a fundamental gap in understanding its biology .

• Structural characterization: Detailed structural studies of ELTD1 and its complexes with binding partners are lacking, limiting rational drug design efforts .

• Tissue-specific functions: How ELTD1 functions differ across tissues and disease states requires further clarification, particularly given contradictory findings regarding its prognostic significance .

• Therapeutic optimization: While antibody treatments show promise, optimal targeting strategies, dosing regimens, and combination approaches need further investigation .

• Biomarker validation: Despite promising preclinical data, clinical validation of ELTD1 as a biomarker for disease diagnosis, prognosis, or treatment selection requires larger studies .